STAAR Surgical (STAA)

• Market cap: $901M
• 1 day: -1.51%
• 5 days: 4.16%
• 1 month: 3.57%
• 3 months: -23.82%
• 6 months: -38.08%
• Year to date: -24.23%
• 1 year: -60.27%
• 5 years: -52.35%
• 10 years: 106.33%
• Sector: Healthcare
• Industry: Medical Instruments & Supplies

About: Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.

Employees: 1,211

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

1% less repeat investments, than reductions

Existing positions increased: 74 | Existing positions reduced: 75

1.37% less ownership

Funds ownership: 99.54% [Q3] → 98.17% (-1.37%) [Q4]

10% less funds holding

Funds holding: 233 [Q3] → 210 (-23) [Q4]

35% less capital invested

Capital invested by funds: $1.82B [Q3] → $1.18B (-$643M) [Q4]

40% less first-time investments, than exits

New positions opened: 29 | Existing positions closed: 48

42% less call options, than puts

Call options by funds: $2.4M | Put options by funds: $4.12M

50% less funds holding in top 10

Funds holding in top 10: 6 [Q3] → 3 (-3) [Q4]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $16 12% downside
• Avg. target: $17.40 5% downside
• High target: $20 10% upside

5 analyst ratings

• positive: 1 20%
• neutral: 4 80%
• negative: 0 0%

Wells Fargo	7% downside $17	Equal-Weight Initiated	21 Apr 2025
Stephens & Co. Mason Carrico 15% 1-year accuracy 4 / 26 met price target	7% downside $17	Equal-Weight Reiterated	18 Mar 2025
Canaccord Genuity Jon Young 38% 1-year accuracy 3 / 8 met price target	7% downside $17	Hold Maintained	13 Feb 2025
Stifel Thomas Stephan 33% 1-year accuracy 4 / 12 met price target	10% upside $20	Buy Maintained	12 Feb 2025
Piper Sandler Matt O'Brien 46% 1-year accuracy 23 / 50 met price target	12% downside $16	Neutral Maintained	12 Feb 2025